1. 1Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–498. MEDLINE |
CrossRef
2. 2Fougerolles AD, Manoharan M, Meyers R, Vornlocher HP, Engelke DR, Rossi JJ. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics. Methods Enzymol. 2005;392:278–296. MEDLINE |
CrossRef
3. 3Leung RKM, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther. 2005;107:222–239. MEDLINE |
CrossRef
4. 4Oliveira S, Storm G, Schiffelers R. Targeted delivery of siRNA. J Biomed Biotechnol. 2006;2006:63675.
5. 5Sharp PA. RNAi and double-strand RNA. Genes Dev. 1999;13:139–141. MEDLINE |
CrossRef
6. 6Caplen N. Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther. 2004;11:1241–1248. MEDLINE |
CrossRef
7. 7Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell. 1990;2:279–289.
CrossRef
8. 8Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–811. MEDLINE |
CrossRef
9. 9Sah DWY. Therapeutic potential of RNA interference for neurological disorders. Life Sci. 2006;79:1773–1780. MEDLINE |
CrossRef
10. 10Stahel RA, Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy—an overview. Lung Cancer. 2003;41:81–88. Abstract | Full Text |
Full-Text PDF (215 KB)
|
CrossRef
11. 11Emilsson GM, Nakamura S, Roth A, Breaker RR. Ribozyme speed limits. RNA. 2003;9:907–918. MEDLINE |
CrossRef
12. 12Doudna JA, Cech TR. The chemical repertoire of natural ribozymes. Nature. 2002;418:222–228. MEDLINE |
CrossRef
13. 13Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 2002;296:1000–1004.
CrossRef
14. 14Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF. Efficient Reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem. 2003;278:7108–7118. MEDLINE |
CrossRef
15. 15Layzer JM, McCaffrey AP, Tanner AK, Huang ZAN, Kay MA, Sullenger BA. In vivo activity of nuclease-resistant siRNAs. RNA. 2004;10:766–771. MEDLINE |
CrossRef
16. 16Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, et al. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology. 2005;41:1349–1356. MEDLINE |
CrossRef
17. 17Zimmermann TS, Lee ACH, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111–114.
CrossRef
18. 18Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006;13:541–552. MEDLINE |
CrossRef
19. 19Gallo M, Kretschmer-Kazemi Far R, Sczakiel G, Iribarren A. Activity and stability of hammerhead ribozymes containing 2′-C-methyluridine: a new RNA mimic. Chem Biodivers. 2005;2:198–204.
CrossRef
20. 20Hendry P, McCall M, Stewart T, Lockett T. Redesigned and chemically-modified hammerhead ribozymes with improved activity and serum stability. BMC Chem Biol. 2004;4:1.
21. 21Sall A, Liu Z, Zhang HM, Yuan J, Lim T, Su Y, et al. MicroRNAs-based therapeutic strategy for virally induced diseases. Curr Drug Discov Technol. 2008;5:49–58.
CrossRef
22. 22Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, et al. From the cover: RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005;102:5820–5825. MEDLINE |
CrossRef
23. 23Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther. 2005;12:618–633. MEDLINE |
CrossRef
24. 24Gewirtz AM. RNA targeted therapeutics for hematologic malignancies. Blood Cells Mol Dis. 2007;38:117–119. MEDLINE |
CrossRef
25. 25Rohl T, Kurreck J. RNA interference in pain research. J Neurochem. 2006;99:371–380. MEDLINE |
CrossRef
26. 26Christoph T, Grunweller A, Mika J, Schafer MKH, Wade EJ, Weihe E, et al. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun. 2006;350:238–243.
CrossRef
27. 27Hickerson RP, Smith FJD, Irwin Mclean WH, Landthaler M, Leube RE, Kaspar RL. SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita. Ann NY Acad Sci. 2006;1082:56–61. MEDLINE |
CrossRef
28. 28Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nature Rev Drug Discov. 2004;3:318–329.
29. 29Persengiev SP, Zhu X, Green MR. Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA. 2004;10:12–18. MEDLINE |
CrossRef
30. 30Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BRG. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol. 2003;5:834–839. MEDLINE |
CrossRef
31. 31Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet. 2003;34:263–264. MEDLINE |
CrossRef
32. 32Xu J, Li L, Hong J, Huang W. Effects of small interference RNA against PTP1B and TCPTP on insulin signaling pathway in mouse liver: evidence for non-synergetic cooperation. Cell Biol Int. 2007;31:88–91. MEDLINE |
CrossRef
33. 33Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther. 2006;13:644–670. MEDLINE |
CrossRef
34. 34Li XZJ, Lu MQ, Yang Y, Xu C, Li H, Wang GS, et al. Alleviation of ischemia-reperfusion injury in rat liver transplantation by induction of small interference RNA targeting Fas. Langenbecks Arch Surg. 2007;392:345–351. MEDLINE |
CrossRef
35. 35Zhang XZX, Sun H, Feng B, Chen G, Vladau C, Li M, et al. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation. 2006;82:1728–1732. MEDLINE |
CrossRef
36. 36Zender LKS. Suppression of apoptosis in the liver by systemic and local delivery of small-interfering RNAs. Methods Mol Biol. 2007;361:217–226. MEDLINE
37. 37Shin D, Kim SI, Kim M, Park M. Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. Virus Res. 2006;119:146–153. MEDLINE |
CrossRef
38. 38Hino T, Yokota T, Ito S, Nishina K, Kang YS, Mori S, et al. In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem Biophys Res Commun. 2006;340:263–267.
CrossRef
39. 39Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet. 2005;54:3–20. MEDLINE
40. 40Koller E, Propp S, Murray H, Lima W, Bhat B, Prakash TP, et al. Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res. 2006;34:4467–4476.
CrossRef
41. 41Nawrot B, Sipa K. Chemical and structural diversity of siRNA molecules. Curr Top Med Chem. 2006;6:913–925. MEDLINE |
CrossRef
42. 42Kunisawa J, Masuda T, Katayama K, Yoshikawa T, Tsutsumi Y, Akashi M, et al. Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J Control Release. 2005;105:344–353. MEDLINE |
CrossRef
43. 43Moschos SA, Williams AE, Lindsay MA. Cell-penetrating-peptide-mediated siRNA lung delivery. Biochem Soc Trans. 2007;35:807–810.
44. 44Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev. 2007;59:134–140.
CrossRef
45. 45Song E, Zhu P, Lee S-K, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005;23:709–717. MEDLINE |
CrossRef
46. 46Vornlocher HP. Antibody-directed cell-type-specific delivery of siRNA. Trends Mol Med. 2006;12:1–3. MEDLINE |
CrossRef
47. 47Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006;13:1222–1234. MEDLINE |
CrossRef
48. 48Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng. 2007;97:909–921. MEDLINE |
CrossRef
49. 49Fan Y, Xin X, Chen B, Ma X. Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo. Pathology. 2006;38:561–567.
50. 50Furset G, Sioud M. Design of bifunctional siRNAs: combining immunostimulation and gene-silencing in one single siRNA molecule. Biochem Biophys Res Commun. 2007;352:642–649.
CrossRef
51. 51Hagemann C, Meyer C, Stojic J, Eicker S, Gerngras S, Kuhnel S, et al. High efficiency transfection of glioma cell lines and primary cells for overexpression and RNAi experiments. J Neurosci Methods. 2006;156:194–202. MEDLINE |
CrossRef
52. 52Michaela M, Hana K, Radim B, Hana B. Targeting of gene expression by siRNA in CML primary cells. Mol Biol Rep. 2007;34:27–33. MEDLINE |
CrossRef
53. 53Chen G, Dong Q, Zhang J, Fu F, Xu Z, Liang Q, et al. Knockdown of PLK1 mRNA by special siRNA. Yi Chuan. 2006;28:21–25. MEDLINE
54. 54Zhang M, Guller S, Huang Y. Method to enhance transfection efficiency of cell lines and placental fibroblasts. Placenta. 2008;28:779–782.
55. 55Xu RX, Tu YY, Jiang XD, Feng JN, Huang J. Apoptosis of glioma cell line U251 induced by small interfering RNA targeting survivin. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26:398–401. MEDLINE
56. 56Grayson ACR, Ma J, Putnam D. Kinetic and efficacy analysis of RNA interference in stably and transiently expressing cell lines. Mol Pharmaceutics. 2006;3:601–613.
57. 57LI GY, Fan B, Wu YZ, Wang XR, Wang YH, Wu JX. Inhibition of vascular endothelial growth factor gene expression by T7-siRNAs in cultured human retinal pigment epithelial cells. Chin Med J. 2005;118:567–573.
58. 58Golzio M, Mazzolini L, Ledoux A, Paganin A, Izard M, Hellaudais L, et al. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther. 2007;14:752–759. MEDLINE |
CrossRef
59. 59Bejjani RA, Andrieu C, Bloquel C, Berdugo M, BenEzra D, Behar-Cohen F. Electrically assisted ocular gene therapy. Survey Ophthalmol. 2007;52:196–208.
60. 60Heller R, Jaroszeski M, Atkin A, Moradpour D, Gilbert R, Wands J, et al. In vivo gene electroinjection and expression in rat liver. FEBS Lett. 1996;389:225–228. Abstract |
Full-Text PDF (388 KB)
|
CrossRef
61. 61Pardridge WM. shRNA and siRNA delivery to the brain. Adv Drug Deliv Rev. 2007;59:141–152.
CrossRef
62. 62Sioud M. RNAi therapy: antibodies guide the way. Gene Ther. 2005;13:194–195. MEDLINE |
CrossRef
63. 63Yutaka I, Kazunari T. Ligand-targeted delivery of therapeutic siRNA. Pharm Res. 2006;23:1631–1640. MEDLINE |
CrossRef
64. 64Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004;32:e149.
CrossRef
65. 65Cardoso A, Simões S, de Almeida L, Pelisek J, Culmsee C, Wagner E, et al. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J Gene Med. 2007;9:170–183.
CrossRef
66. 66Choi JS, MacKay JA, Szoka FC. Low-pH-sensitive PEG-stabilized plasmid-lipid nanoparticles: preparation and characterization. Bioconjug Chem. 2003;14:420–429. MEDLINE |
CrossRef
67. 67Shao K, Hou Q, Go M, Duan W, Cheung N, Feng S, et al. Sulfatide-tenascin interaction mediates binding to the extracellular matrix and endocytic uptake of liposomes in glioma cells. Cell Mol Life Sci. 2007;64:506–515.
CrossRef
68. 68Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007—an update. J Gene Med. 2007;9:833–842.
CrossRef
69. 69Sioud M, Sorensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun. 2003;312:1220–1225.
CrossRef
70. 70Bouxsein NF, McAllister CS, Ewert KK, Samuel CE, Safinya CR. Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry. 2007;46:4785–4792.
71. 71Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry. 2004;43:13348–13356.
72. 72Wang Y, Gao S, Ye W-H, Yoon HS, Yang Y-Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater. 2006;5:791–796. MEDLINE |
CrossRef
73. 73Kakizawa Y, Furukawa S, Kataoka K. Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. J Control Release. 2004;97:345–356. MEDLINE |
CrossRef
74. 74Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115:216–225. MEDLINE |
CrossRef
75. 75Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res. 2007;47:1202–1208. MEDLINE |
CrossRef
76. 76Nedjma T, Jean-Rémi B, Ali T, Hind E, Hervé H, Andrei M, et al. Efficacy of siRNA nanocapsules targeted against the EWS–Fli1 oncogene in Ewing sarcoma. Pharm Res. 2006;23:892–900. MEDLINE |
CrossRef
77. 77Lee H, Mok H, Lee S, Oh YK, Park TG. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release. 2007;119:245–252.
CrossRef
78. 78Segura T, Hubbell JA. Synthesis and in vitro characterization of an ABC triblock copolymer for siRNA delivery. Bioconjug Chem. 2007;18:736–745. MEDLINE |
CrossRef
79. 79Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A. 2005;102:12177–12182. MEDLINE |
CrossRef
80. 80Svintradze DV, Mrevlishvili GM. Fiber molecular model of atelocollagen-small interfering RNA (siRNA) complex. Int J Biol Macromol. 2005;37:283–286. MEDLINE |
CrossRef
81. 81Minakuchi Y, Takeshita F, Kosaka N, Sasaki H, Yamamoto Y, Kouno M, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 2004;32:e109.
CrossRef
82. 82Grzelinski M, Urban-Klein B, Martens T, Lamszus K, Bakowsky U, Höbel S, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther. 2006;17:751–766. MEDLINE |
CrossRef
83. 83Crombez L, Charnet A, Morris MC, Aldrian-Herrada G, Heitz F, Divita G. A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans. 2007;35:44–46. MEDLINE |
CrossRef
84. 84Vogel V, Lochmann D, Weyermann J, Mayer G, Tziatzios C, van den Broek JA, et al. Oligonucleotide-protamine-albumin nanoparticles: preparation, physical properties, and intracellular distribution. J Control Release. 2005;103:99–111. MEDLINE |
CrossRef
85. 85Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol. 2006;133:9–29. MEDLINE |
CrossRef
86. 86Ling B, Zhou Y, Feng D, Shen G, Gao T, Shi Y, et al. Down-regulation of EDAG expression by retrovirus-mediated small interfering RNA inhibits the growth and IL-8 production of leukemia cells. Oncol Rep. 2007;18:659–664.
87. 87Jeong Soon J, So Yeon K, Sang Bong L, Kyung Ok K, Joong Soo H, Young Moo L. Poly(ethylene glycol)/poly([epsilon]-caprolactone) diblock copolymeric nanoparticles for non-viral gene delivery: the role of charge group and molecular weight in particle formation, cytotoxicity and transfection. J Control Release. 2006;113:173–182. MEDLINE |
CrossRef
88. 88Li L, Yang L, Scudiero DA, Miller SA, Yu ZX, Stukenberg PT, et al. Development of recombinant adeno-associated virus vectors carrying small interfering RNA (shHec1)-mediated depletion of kinetochore Hec1 protein in tumor cells. Gene Ther. 2007;14:814–827. MEDLINE |
CrossRef
89. 89Fang C, Shi B, Pei Y-Y, Hong M-H, Wu J, Chen H-Z. In vivo tumor targeting of tumor necrosis factor-[alpha]-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci. 2006;27:27–36. MEDLINE |
CrossRef
90. 90Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2004;377:159–169.
CrossRef
91. 91Zuhorn I, Kalicharan R, Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J Biol Chem. 2002;277:18021–18028. MEDLINE |
CrossRef
92. 92De Smedt SC, Demeester J, Hennink WE. Cationic polymer based gene delivery systems. Pharm Res. 2000;17:113–126. MEDLINE |
CrossRef
93. 93Akin A. Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J Gene Med. 2005;7:657–663.
CrossRef
94. 94Grayson AC, Doody A, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res. 2006;23:1868–1876. MEDLINE |
CrossRef
95. 95Woodle MC. Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliv Rev. 1998;32:139–152.
CrossRef
96. 96Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73:137–172. MEDLINE |
CrossRef
97. 97Kataoka K, Itaka K, Nishiyama N, Yamasaki Y, Oishi M, Nagasaki Y. Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Acids Res Suppl. 2005;49:17–18.
98. 98Hirsch-Lerner D, Zhang M, Eliyahu H, Ferrari ME, Wheeler CJ, Barenholz Y. Effect of “helper lipid” on lipoplex electrostatics. Biochim Biophys Acta. 2005;1714:71–84. MEDLINE
99. 99Zimmer A, Atmaca-Abdel A, Gilbert M, Werner D, Noe C. Synthesis of cholesterol modified cationic lipids for liposomal drug delivery of antisense oligonucleotides. Eur J Pharm Biopharm. 1999;47:175–178. MEDLINE |
CrossRef
100. 100Leng Q, Goldgeier L, Zhu J, Cambell P, Ambulos N, Mixson AJ. Histidine-lysine peptides as carriers of nucleic acids. Drug News Perspect. 2007;20:77–86. MEDLINE |
CrossRef
101. 101Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 2004;12:461–466. MEDLINE |
CrossRef
102. 102Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002–1007. MEDLINE |
CrossRef
103. 103Lochmann D, Weyermann J, Georgens C, Prassl R, Zimmer A. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: Physicochemical characterization. Eur J Pharm Biopharm. 2005;59:419–429. MEDLINE |
CrossRef
104. 104Weyermann J, Lochmann D, Georgens C, Zimmer A. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: Cellular uptake and effect. Eur J Pharm Biopharm. 2005;59:431–438. MEDLINE |
CrossRef
105. 105Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000;60:249–271. MEDLINE |
CrossRef
106. 106Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol. 1995;49:807–838. MEDLINE
107. 107Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J. 1997;11:615–623. MEDLINE
108. 108Verma IM, Somia N. Gene therapy—promises, problems and prospects. Nature. 1997;389:239–242. MEDLINE |
CrossRef
109. 109Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, et al. Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther. 2004;10:162–171. MEDLINE |
CrossRef
110. 110Zhao L-J, Jian H, Zhu H. Specific gene inhibition by adenovirus-mediated expression of small interfering RNA. Gene. 2003;316:137–141. MEDLINE |
CrossRef
111. 111Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol. 1990;10:4239–4242. MEDLINE
112. 112Lewis P, Hensel M, Emerman M. Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J. 1992;11:3053–3058. MEDLINE
113. 113Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–267. MEDLINE
114. 114Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A. 1997;94:10319–10323. MEDLINE |
CrossRef
115. 115Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 1997;71:6641–6649.
116. 116Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology. 2007;46:200–208. MEDLINE |
CrossRef
117. 117Chiu Y-L, Ali A, Chu C-y, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol. 2004;11:1165–1175. MEDLINE |
CrossRef
118. 118Berezhna SY, Supekova L, Supek F, Schultz PG, Deniz AA. siRNA in human cells selectively localizes to target RNA sites. Proc Natl Acad Sci U S A. 2006;103:7682–7687. MEDLINE |
CrossRef